AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20100748 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 366
Study 18554192 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced AAI/R pacing (MVP)
Number of subjects: 121
Study 18554192 — intervention group
Group type: COMPARATOR
Intervention: DDD/R pacing (Control)
Number of subjects: 121
Study 15682367 — intervention group
Group type: EXPERIMENTAL
Intervention: New method of quantification (TPD)
Number of subjects: 80
Study 15682367 — intervention group
Group type: COMPARATOR
Intervention: Visual scoring
Number of subjects: 80
Study 15682367 — intervention group
Group type: COMPARATOR
Intervention: Standard quantification
Number of subjects: 80
Study 12085609 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional neuromuscular stimulation (FNS)
Number of subjects: 7
Study 12085609 — intervention group
Group type: COMPARATOR
Intervention: Able-bodied standing
Number of subjects: 7
Study 10189121 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg glucose
Number of subjects: 10
Study 10189121 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g/kg glucose
Number of subjects: 10
Study 7750002 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in house dust mite allergen Der p I exposure
Number of subjects: 34
Study 7750002 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in house dust mite allergen concentration in the living room floor
Number of subjects: 34
Study 2405736 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.15 mg/kg
Number of subjects: 126
Study 2405736 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 126
Study 6311913 — intervention group
Group type: EXPERIMENTAL
Intervention: DPT + PRP vaccine
Number of subjects: 78
Study 6311913 — intervention group
Group type: COMPARATOR
Intervention: DPT vaccine
Number of subjects: 78
Study 30523712 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax-rituximab
Number of subjects: 194
Study 30523712 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine-rituximab
Number of subjects: 194
Study 29726319 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based chemotherapy (group A: four treatments at home followed by three in an outpatient clinic)
Number of subjects: 51
Study 29726319 — intervention group
Group type: COMPARATOR
Intervention: Outpatient chemotherapy (group B: three treatments in an outpatient clinic followed by four at home)
Number of subjects: 51
Study 26730818 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV/r 500/100 mg
Number of subjects: 0
Study 26730818 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV/r 500/200 mg
Number of subjects: 0
Study 26730818 — intervention group
Group type: COMPARATOR
Intervention: LPV/r 400/100 mg
Number of subjects: 0
Study 25022299 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial sealant (InteguSeal)
Number of subjects: 96
Study 25022299 — intervention group
Group type: COMPARATOR
Intervention: Plain adhesive drape (control group)
Number of subjects: 96
Study 22822007 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA risk assessment communication
Number of subjects: 497
Study 22822007 — intervention group
Group type: COMPARATOR
Intervention: Standard risk assessment communication
Number of subjects: 497
Study 20652333 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol at 30 μg/kg/min
Number of subjects: 30
Study 20652333 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 30
Study 17211705 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg omeprazole once daily
Number of subjects: 8
Study 17211705 — intervention group
Group type: COMPARATOR
Intervention: 20 mg famotidine twice daily
Number of subjects: 8
Study 17025373 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin E supplementation
Number of subjects: 72
Study 17025373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 12719045 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium (0.9 mg kg(‐1))
Number of subjects: 20
Study 12719045 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium (0.25 mg kg(‐1))
Number of subjects: 20
Study 11303324 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated homocysteine levels in CAD patients (mean 13.61 +/- 4.5 mumol/L)
Number of subjects: 100
Study 11303324 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated homocysteine level defined as > or = 12.83 mumol/L
Number of subjects: 100
Study 11303324 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mumol/L increment in homocysteine level
Number of subjects: 100
Study 11303324 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated homocysteine level
Number of subjects: 100
Study 11303324 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine levels in patients with elevated levels
Number of subjects: 100
Study 11303324 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between homocysteine and folate levels
Number of subjects: 100
Study 11303324 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between homocysteine and vitamin B12 concentrations
Number of subjects: 100
Study 9019574 — intervention group
Group type: EXPERIMENTAL
Intervention: Spersallerg eye drops
Number of subjects: 47
Study 1290619 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (DuP 753, MK‐954) at doses of 5, 10, 20, 40, 80, and 120 mg
Number of subjects: 0
Study 1290619 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (DuP 753, MK‐954)
Number of subjects: 0
Study 6365501 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-glucose self-testing (5 tests daily)
Number of subjects: 27
Study 6365501 — intervention group
Group type: COMPARATOR
Intervention: Self-testing of urinary glucose (4 tests)
Number of subjects: 27
Study 29625857 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE programme
Number of subjects: 66
Study 29625857 — intervention group
Group type: COMPARATOR
Intervention: Usual institutional management (Control)
Number of subjects: 66
Study 28749745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-alcohol episode with no epilogue
Number of subjects: 0
Study 28749745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-alcohol episode with epilogue
Number of subjects: 0
Study 28749745 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-alcohol episode with epilogue
Number of subjects: 0
Study 26775514 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation (Δ50%W intensity, 30 min/day, 5 days/week for 12 weeks)
Number of subjects: 10
Study 26775514 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 10
Study 23958540 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide 290 μg once daily for 26 weeks
Number of subjects: 805
Study 23958540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 805
Study 21081243 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (0.04 mg/kg subcutaneously once daily; n = 5)
Number of subjects: 9
Study 21081243 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 9
Study 18182396 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG stimulation
Number of subjects: 104
Study 18182396 — intervention group
Group type: COMPARATOR
Intervention: FSH stimulation
Number of subjects: 104
Study 16084677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent catheterization (IMC group)
Number of subjects: 81
Study 16084677 — intervention group
Group type: COMPARATOR
Intervention: Indwelling catheterization (IDC group)
Number of subjects: 81
Study 12509304 — intervention group
Group type: EXPERIMENTAL
Intervention: NEO‐FFI (Neuroticism, Extraversion and Other ‐ Five‐Factor Inventory)
Number of subjects: 0
Study 10834715 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/day of rHGH
Number of subjects: 28
Study 10834715 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 28
Study 8864715 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg t.i.d. for 9 months
Number of subjects: 289
Study 8864715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 1741200 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous amoxicillin (twice a day every day for up to 4 months)
Number of subjects: 55
Study 1741200 — intervention group
Group type: COMPARATOR
Intervention: Intermittent amoxicillin (twice a day only when respiratory symptoms developed for up to 4 months)
Number of subjects: 55
Study 1741200 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous amoxicillin
Number of subjects: 55
Study 1741200 — intervention group
Group type: COMPARATOR
Intervention: Intermittent amoxicillin
Number of subjects: 55
Study 6535988 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 60
Study 6535988 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined method (brachytherapy and surgery)
Number of subjects: 60
Study 6535988 — intervention group
Group type: EXPERIMENTAL
Intervention: Teletherapy with radical operation
Number of subjects: 60
Study 31972848 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy-focused Type 2 diabetes self-management intervention
Number of subjects: 250
Study 31972848 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 250
Study 30878711 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin Skin Test Kit (containing penicilloyl polylysine, minor determinant mixture, and amoxicillin)
Number of subjects: 455
Study 30878711 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin challenge (250 mg)
Number of subjects: 455
Study 27905821 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of booster hepatitis B vaccination (0-1-6 month, 20 µg)
Number of subjects: 225
Study 27905821 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (1.0 to <10.0 mIU/mL)
Number of subjects: 225
Study 25876795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Methods adherence (within-patient)
Number of subjects: 57
Study 25876795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Methods adherence (between-patient)
Number of subjects: 57
Study 24310853 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-IP approach
Number of subjects: 4
Study 24310853 — intervention group
Group type: COMPARATOR
Intervention: LA-OP approach
Number of subjects: 4
Study 23046320 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB)
Number of subjects: 50
Study 23046320 — intervention group
Group type: COMPARATOR
Intervention: Conventional angioplasty balloon (AB)
Number of subjects: 50
Study 19573752 — intervention group
Group type: EXPERIMENTAL
Intervention: Woven polyester grafts
Number of subjects: 303
Study 19573752 — intervention group
Group type: COMPARATOR
Intervention: Expanded polytetrafluoroethylene (ePTFE) grafts
Number of subjects: 303
Study 17296571 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency ERT (once every 4 weeks)
Number of subjects: 11
Study 17296571 — intervention group
Group type: COMPARATOR
Intervention: Standard frequency ERT (once every week or fortnight)
Number of subjects: 11
Study 15572495 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (10 mg)
Number of subjects: 2065
Study 15572495 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel (2 doses of 750 microg given 12 hours apart)
Number of subjects: 2065
Study 15572495 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 2065
Study 11242382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrel‐Dubousset instrumentation
Number of subjects: 70
Study 11242382 — intervention group
Group type: COMPARATOR
Intervention: No instrumentation
Number of subjects: 70
Study 9272334 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPwc
Number of subjects: 0
Study 9272334 — intervention group
Group type: COMPARATOR
Intervention: DTaP vaccines
Number of subjects: 0
Study 9272334 — intervention group
Group type: COMPARATOR
Intervention: DT vaccines
Number of subjects: 0
Study 8354869 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated disinfection with 2% glutaraldehyde and 70% alcohol rinse
Number of subjects: 60
Study 8354869 — intervention group
Group type: COMPARATOR
Intervention: Manual disinfection with 2% glutaraldehyde and 70% alcohol rinse
Number of subjects: 60
Study 8354869 — intervention group
Group type: EXPERIMENTAL
Intervention: Both automated and manual disinfection
Number of subjects: 60
Study 8354869 — intervention group
Group type: COMPARATOR
Intervention: Manual disinfection
Number of subjects: 60
Study 8354869 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated disinfection
Number of subjects: 60
Study 8354869 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopes (general)
Number of subjects: 60
Study 3725520 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Number of subjects: 22
Study 3725520 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 31763316 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional endoscopic sinus surgery (Group A)
Number of subjects: 0
Study 31763316 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (Group B)
Number of subjects: 0
Study 29348382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophiocephalus striatus extract (10 g per day for 14 days)
Number of subjects: 109
Study 29348382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 26643931 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVc
Number of subjects: 2055
Study 26643931 — intervention group
Group type: COMPARATOR
Intervention: TIVf
Number of subjects: 2055
Study 24512337 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour intimate touch instructional laboratory with subsequent clinical experience
Number of subjects: 0
Study 24512337 — intervention group
Group type: COMPARATOR
Intervention: Clinical experience only (control group)
Number of subjects: 0
Study 22504513 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stent implantation
Number of subjects: 50
Study 22504513 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 50
Study 19574917 — intervention group
Group type: EXPERIMENTAL
Intervention: Lissamine green (LG)
Number of subjects: 30
Study 19574917 — intervention group
Group type: COMPARATOR
Intervention: Rose bengal (RB)
Number of subjects: 30
Study 19574917 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LG and RB
Number of subjects: 30
Study 17697449 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (90 mg daily)
Number of subjects: 816
Study 17697449 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (120 mg daily)
Number of subjects: 816
Study 17697449 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo to etoricoxib (90 mg)
Number of subjects: 816
Study 17697449 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg twice daily)
Number of subjects: 816
Study 15138671 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (DX, n=10)
Number of subjects: 30
Study 15138671 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (DO, n=10)
Number of subjects: 30
Study 15138671 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (DA, n=10)
Number of subjects: 30
Study 12009282 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66/QS-21 vaccine
Number of subjects: 89
Study 12009282 — intervention group
Group type: COMPARATOR
Intervention: SPf66/alum vaccine
Number of subjects: 89
Study 10233114 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive-strength training (32% of training volume)
Number of subjects: 18
Study 10233114 — intervention group
Group type: COMPARATOR
Intervention: Control group (3% of training volume explosive-type strength training)
Number of subjects: 18
Study 7744475 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard reaming technique
Number of subjects: 19
Study 7744475 — intervention group
Group type: COMPARATOR
Intervention: Modified reaming technique
Number of subjects: 19
Study 2169783 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg, single prophylactic dose)
Number of subjects: 227
Study 2169783 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg, additional doses)
Number of subjects: 227
Study 2169783 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg)
Number of subjects: 227
Study 2169783 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine plus dexamethasone (conventional anti-emetic regimen)
Number of subjects: 227
Study 7301160 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative skin disinfection with povidone-iodine 10% (Betadine) and application of 10% povidone-iodine solution before skin closure.
Number of subjects: 220
Study 7301160 — intervention group
Group type: COMPARATOR
Intervention: Preoperative skin disinfection with alcohol 70% and iodine-tincture 2%, and disinfection with iodine before skin suturing.
Number of subjects: 220
Study 31569652 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen waterway trail open (10 km, 8-10 weeks)
Number of subjects: 466
Study 31569652 — intervention group
Group type: COMPARATOR
Intervention: Land-based trails accessible before and after the intervention
Number of subjects: 466
Study 28274889 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 50,000 IU monthly for 24 months
Number of subjects: 413
Study 28274889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 26466468 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar locking compression plate
Number of subjects: 122
Study 26466468 — intervention group
Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 122
Study 23999674 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AA group: 1 g/kg/d of parenteral amino acids, increasing by 1 g/kg daily until a maximum of 4 g/kg/d
Number of subjects: 150
Study 23999674 — intervention group
Group type: COMPARATOR
Intervention: High AA group: 3 g/kg/d of parenteral amino acids, increasing by 1 g/kg daily until a maximum of 4 g/kg/d
Number of subjects: 150
Study 21403636 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg sublingual testosterone (with hydroxypropyl‐β‐cyclodextrin carrier)
Number of subjects: 121
Study 21403636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 19016815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics (ciprofloxacin and metronidazole)
Number of subjects: 79
Study 19016815 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics (ciprofloxacin and metronidazole)
Number of subjects: 79
Study 17942000 — intervention group
Group type: EXPERIMENTAL
Intervention: e-mail with attachment I (short one)
Number of subjects: 119
Study 17942000 — intervention group
Group type: EXPERIMENTAL
Intervention: e-mail with attachment II (long one)
Number of subjects: 119
Study 17942000 — intervention group
Group type: COMPARATOR
Intervention: no information (control)
Number of subjects: 119
Study 12795852 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome at 135 mg/m² each session, combined with ADM or DDP for two cycles (3 weeks per cycle)
Number of subjects: 129
Study 12795852 — intervention group
Group type: COMPARATOR
Intervention: Traditional taxol at 135 mg/m² each session, combined with ADM or DDP for two cycles (3 weeks per cycle)
Number of subjects: 129
Study 12795852 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome
Number of subjects: 129
Study 12795852 — intervention group
Group type: COMPARATOR
Intervention: Traditional taxol
Number of subjects: 129
Study 11017151 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered peptide ligand of myelin basic protein (5 mg)
Number of subjects: 0
Study 11017151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8634809 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% glycolic acid applied topically for 5 minutes once weekly for 4 weeks
Number of subjects: 41
Study 8634809 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 41
Study 1486710 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-cysteine
Number of subjects: 137
Study 1486710 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-methionine-methyl sulphonium chloride
Number of subjects: 137
Study 1486710 — intervention group
Group type: COMPARATOR
Intervention: Graduated compression bandaging
Number of subjects: 137
Study 6511520 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia with radiation
Number of subjects: 161
Study 6511520 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia alone
Number of subjects: 161
Study 2873863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous somatostatin (100 micrograms/h)
Number of subjects: 6
Study 2873863 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 6
Study 31962348 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based rehabilitation treatments
Number of subjects: 0
Study 31962348 — intervention group
Group type: COMPARATOR
Intervention: Alternative research designs (e.g. case-control studies, cohort studies, observational studies)
Number of subjects: 0
Study 29761273 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D observation of a consultant surgeon performing a training task on the daVinci S robotic system
Number of subjects: 90
Study 29761273 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D observation of a consultant surgeon performing a training task on the daVinci S robotic system
Number of subjects: 90
Study 29761273 — intervention group
Group type: COMPARATOR
Intervention: No observation control
Number of subjects: 90
Study 25964375 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation within 3 hours of last known well
Number of subjects: 137
Study 25964375 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer onset to door (OTD) intervals
Number of subjects: 137
Study 25964375 — intervention group
Group type: EXPERIMENTAL
Intervention: Time >3 hours
Number of subjects: 137
Study 25964375 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier presentation
Number of subjects: 137
Study 25964375 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to presentation
Number of subjects: 137
Study 24708232 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based counseling using principles of motivational interviewing and telehealth home monitoring
Number of subjects: 19